TY - JOUR
T1 - Associations of Hemostatic Variables with Cardiovascular Disease and Total Mortality
T2 - The Glasgow MONICA Study
AU - Lowe, Gordon
AU - Peters, Sanne A. E.
AU - Rumley, Ann
AU - Tunstall-pedoe, Hugh
AU - Woodward, Mark
N1 - Funding Information:
This study was funded by the Chief Scientist Office, Department of Health, Scottish Office; the views expressed in this report are those of the authors and not necessarily of this office.
PY - 2022/3/4
Y1 - 2022/3/4
N2 - The associations of plasma levels of haemostatic factors, other than fibrinogen, with risks of cardiovascular disease and allcause mortality are not well defined. In two phases of the Glasgow MONICA Study, we assayed coagulation factors (VII, VIII, IX and von Willebrand factor, VWF), coagulation inhibitors (antithrombin, protein C, protein S), coagulation activation markers (prothrombin F1+2, thrombin-antithrombin [TAT] complexes, D-dimer), and the fibrinolytic factors tissue plasminogen activator antigen (t-PA) and plasminogen activator inhibitor (PAI-1). Over 15-20 years, we followed-up between 382 and 1123 men and women aged 30-74 years, without baseline CVD, for risks of CVD and mortality. Age and sex adjusted hazard ratios (HRs) for CVD (top third versus bottom third) were significant only for Factor VIII (1.30; 95% CI 1.06, 1.58) and Factor IX (1.18; 1.01, 1.39); these HRs were attenuated by further adjustment for CVD risk factors: 1.17; 0.94, 1.46, and 1.07; 0.92, 1.25, respectively. In contrast, Factor VIII, D-dimer and t-PA were strongly associated with mortality after full risk factor adjustment: respectively, 1.63 (1.35, 1.96), 2.34 (1.26; 4.35) and 2.81 (1.43, 5.54). Further studies, including meta-analyses, are required to assess the associations of these haemostatic factors with the risks of stroke and heart disease and causes of mortality.
AB - The associations of plasma levels of haemostatic factors, other than fibrinogen, with risks of cardiovascular disease and allcause mortality are not well defined. In two phases of the Glasgow MONICA Study, we assayed coagulation factors (VII, VIII, IX and von Willebrand factor, VWF), coagulation inhibitors (antithrombin, protein C, protein S), coagulation activation markers (prothrombin F1+2, thrombin-antithrombin [TAT] complexes, D-dimer), and the fibrinolytic factors tissue plasminogen activator antigen (t-PA) and plasminogen activator inhibitor (PAI-1). Over 15-20 years, we followed-up between 382 and 1123 men and women aged 30-74 years, without baseline CVD, for risks of CVD and mortality. Age and sex adjusted hazard ratios (HRs) for CVD (top third versus bottom third) were significant only for Factor VIII (1.30; 95% CI 1.06, 1.58) and Factor IX (1.18; 1.01, 1.39); these HRs were attenuated by further adjustment for CVD risk factors: 1.17; 0.94, 1.46, and 1.07; 0.92, 1.25, respectively. In contrast, Factor VIII, D-dimer and t-PA were strongly associated with mortality after full risk factor adjustment: respectively, 1.63 (1.35, 1.96), 2.34 (1.26; 4.35) and 2.81 (1.43, 5.54). Further studies, including meta-analyses, are required to assess the associations of these haemostatic factors with the risks of stroke and heart disease and causes of mortality.
KW - haemostasis
KW - prevention
KW - cardiovascular disease
KW - mortality
U2 - 10.1055/s-0042-1747687
DO - 10.1055/s-0042-1747687
M3 - Article
C2 - 35707625
SN - 2512-9465
VL - 06
JO - TH Open
JF - TH Open
IS - 02
ER -
